It brings forth a potential pathway for the development of novel synthetic molecules with more potency to simultaneously inhibit the function of MCT1 and MCT4 or any other novel or pivotal protein being bound by syrosingopine to provide a pharmacologic therapeutic strategy for this very difficult-to-treat MM patient population who continue to experience poor clinical outcomes. Here, SLC16A1 is linked to Miyoshi myopathy.